Lobe Sciences Ltd. is led by our board of directors, management team, and scientific advisors with extensive experience in pharmaceutical development, regulatory execution, and disciplined capital allocation. Leadership oversight is structured to support the Company’s role as a development-focused organization: advancing high-value programs through defined clinical and regulatory milestones and realizing value through strategic partnerships.
OPERATING MODEL
The Company operates as a pharmaceutical development platform and does not maintain internal commercialization or marketing infrastructure. Commercial execution is undertaken through established third-party partners with the scale, expertise, and market presence required for global distribution.
DIRECTORS
Board of Directors
The Board of Directors provides independent oversight of corporate governance, capital allocation, and strategic execution. The Board’s mandate is to ensure alignment with the Company’s development-focused operating model, disciplined capital management, and shareholder interests.
Frederick D. Sancilio, Ph.D.
Chairman & Chief Executive Officer
Dr. Sancilio is a serial healthcare entrepreneur and pharmaceutical executive with decades of leadership in drug development and life sciences innovation. He currently serves as Chief Executive Officer and Chairman of Lobe Sciences Ltd., and is a Principal of Clearway Global, Inc., a pharmaceutical development advisory firm.
View Full Bio
Widely recognized for his foundational role in shaping the modern contract research and development services industry, Dr. Sancilio founded Applied Analytical Industries (AAI) in 1979, one of the first U.S. contract research organizations dedicated to pharmaceutical product development. AAI later became aaiPharma, Inc. and ultimately Alcami, Inc. following reorganization and acquisition.
Throughout his career, he has held executive and board positions in numerous private and public companies, including aaiPharma, Endeavor Pharmaceutical, Alpha Cognition, and TrippBio. He has contributed to the development of more than 40 U.S. drug product patents and authored nearly 100 scientific publications.
Dr. Sancilio serves as a Research Professor at Florida Atlantic University and previously taught chemistry at the University of North Carolina. He earned his MS and Doctorate degrees from Rutgers University and is the author of Prevention Is The Cure!.
Harry R. Jacobson, M.D.
Director
Dr. Jacobson is a nationally recognized physician, academic leader, and healthcare executive with decades of experience in medical education, institutional leadership, and healthcare investment. He serves as Chairman of the Board of Altemia, Inc. and as a Director of Lobe Sciences Ltd., contributing extensive expertise in strategic development and health systems governance.
View Full Bio
After earning his M.D. from the University of Illinois in 1972, Dr. Jacobson completed his internal medicine residency at Johns Hopkins University and nephrology training in Dallas. In 1985, he joined Vanderbilt University as Professor and Director of Nephrology and later became Vice Chancellor for Health Affairs and Chief Executive Officer of Vanderbilt University Medical Center.
During his 12-year tenure leading VUMC, the institution’s annual budget grew from approximately $750 million to $2.5 billion, and its national research ranking advanced into the top ten. He helped establish the Health Care MBA program at Vanderbilt and subsequently led MedCare Investment Funds, overseeing approximately $600 million in healthcare investments. He currently works with W.P. Global Partners managing a portfolio of healthcare companies.
Dr. Jacobson has founded or co-founded multiple companies, including Contact Software and Renal Care Group, and has served on the boards of major companies including Merck and Renal Care Group. He was named Ernst & Young Southeast Entrepreneur of the Year in 2002 and elected to the Tennessee Healthcare Hall of Fame in 2017. He has published more than 100 research works and co-authored Begin Again Now: The Path to Fixing Health Care.
Wesley Ramjeet, B.A., CPA
Director
Mr. Ramjeet is a certified public accountant and seasoned public company executive with more than three decades of experience in corporate finance, governance, and strategic advisory services. He serves as a Director of Lobe Sciences Ltd., bringing disciplined financial oversight and public market experience.
View Full Bio
Mr. Ramjeet is the Founder and Chief Executive Officer of PPMT Strategic Group, a New York-based management consulting firm established in 2009. Since 2003, he has also served as Managing Partner of Profit Planners, Inc., advising growth-stage companies on financial strategy and operational execution. He is the Founder and Chairman of MD Logic Health.
He currently serves as Chairman of SNN, Inc., a financial media company covering the microcap marketplace. Earlier in his career, Mr. Ramjeet was Chief Financial Officer of Youth Stream Media, Inc., a NASDAQ-listed public company. He began his professional career in the Entrepreneurial Services Group at Ernst & Young, LLP, where during a nine-year tenure he advised both private and publicly traded companies in the biotechnology, technology, and media sectors.
Mr. Ramjeet earned his Bachelor’s degree in Accounting from St. John’s University and is a Certified Public Accountant. He is also Co-Founder of Lions Unleashed, a not-for-profit organization supporting immigrants and minority youth through mentorship and financial assistance.
Marco Lucio Mastrodonato
Director
Mr. Mastrodonato is an international biopharmaceutical entrepreneur and executive with extensive experience in company formation, product development, licensing, and strategic transactions across the US and EU. He serves as a Director of Lobe Sciences Ltd., contributing global development and commercialization expertise to the Board.
View Full Bio
He is the Founder and Chief Executive Officer of BMG Pharma SpA, and Chairman and CEO of BMG Aesthetic Srl and BMG BioChemical Srl. Previously, he served as President of Relife Pharma Srl, a dermatology company that was acquired by the Menarini Group in 2015.
Mr. Mastrodonato was the Founder and former Executive Director of Sinclair Pharma plc, listed on the London Stock Exchange, where he led Business Development, Licensing, and Product Development divisions for nine years. Prior to that, he founded Metrodora Therapeutics Inc., a United States biotechnology company focused on systemic inflammation and the treatment of anemia.
Earlier in his career, he served as Business Development Manager in Europe for Applied Analytical Industries, a CDMO and CRO based in North Carolina, and Carrington Laboratories in Dallas, Texas. He currently serves on the Board of Directors of Aileens Pharma Srl.
Nick Karakochuk
Director
Mr. Karakochuk is a corporate and securities lawyer with significant experience advising public and private companies on capital markets transactions, governance, and regulatory compliance. He serves as a Director of Lobe Sciences Ltd., providing legal and securities oversight in support of disciplined corporate execution.
View Full Bio
He is a partner at DuMoulin Black LLP, where his practice focuses on mergers and acquisitions, public and private financings, corporate reorganizations, and securities regulatory matters. He regularly advises issuers on stock exchange requirements, continuous disclosure obligations, and complex strategic transactions.
Mr. Karakochuk has supported numerous companies through growth initiatives, financings, and governance transitions. Since Dr. Sancilio began serving as Chief Executive Officer of Lobe Sciences, he has worked closely with the Company on governance, regulatory compliance, and transactional matters.
EXECUTIVES
Senior Management
Frederick D. Sancilio, Ph.D.
Chairman & Chief Executive Officer
Dr. Sancilio oversees Lobe Sciences’ development platform, capital allocation strategy, and subsidiary structure, with responsibility for advancing programs through defined clinical and regulatory milestones.
He brings more than three decades of experience in pharmaceutical development, regulatory strategy, and asset de-risking, having guided numerous programs from early development through approval and commercialization via partnerships. His background includes founding and leading multiple development-focused organizations and advising pharmaceutical companies on efficient regulatory and clinical execution.
At Lobe Sciences, Dr. Sancilio applies a disciplined, capital-efficient operating model designed to isolate risk, preserve shareholder value, and advance high-quality assets through strategic partnerships.
Mirza Rahimani, CPA, CA
Chief Financial Officer
Mr. Rahimani oversees Lobe Sciences’ financial reporting, public company compliance, and capital management, supporting the Company’s disciplined pharmaceutical development platform and subsidiary-based structure.
He brings over 15 years of experience in financial reporting, corporate governance, and corporate development, with a strong focus on public companies and growth-oriented organizations. His background includes supporting early-stage companies through complex transactions, equity financings, and regulatory compliance across multiple sectors, including life sciences, mining, and technology.
At Lobe Sciences, Mr. Rahimani is responsible for maintaining financial discipline, ensuring transparent disclosure, and aligning capital allocation with the Company’s development-focused strategy and long-term shareholder interests.
Maghsoud Dariani, Ph.D.
Chief Science Officer
Dr. Dariani leads scientific strategy across Lobe Sciences’ development programs, with responsibility for asset evaluation, translational planning, and alignment of scientific decisions with regulatory and development objectives.
He has extensive experience in drug discovery and development across neurological and metabolic indications, with a background spanning pharmaceutical research, clinical translation, and regulatory-facing development programs.
His role ensures that scientific rigor, data quality, and development feasibility are integrated at every stage of Lobe’s platform-driven execution model.
Bob Miller, Ph.D.
Senior Vice President, Quality and Operations
Dr. Miller leads quality systems and operational execution across Lobe Sciences’ development platform, with responsibility for ensuring regulatory readiness, process discipline, and scalable operational infrastructure across the Company’s programs and subsidiaries.
He brings extensive experience overseeing quality and operations within highly regulated pharmaceutical environments, including senior leadership roles at global organizations such as Johnson & Johnson, Pfizer, and Gilead Sciences. His background spans pharmaceutical development, quality systems, and scientific operations at both large scale and growth stage organizations.
At Lobe Sciences, Dr. Miller applies rigorous quality standards and operational discipline to support efficient development execution, risk reduction, and long-term platform scalability.
GOVERNANCE & OVERSIGHT
Lobe Sciences operates under a conservative governance framework designed to support long-term value creation through disciplined execution. Leadership decisions are guided by data, regulatory clarity, and capital efficiency rather than promotional considerations.
ADVISORS
Scientific & Clinical Advisors
Scientific and clinical advisors provide subject-matter expertise supporting the Company’s development programs and regulatory strategy. Advisory roles are focused on scientific review, clinical relevance, and data interpretation rather than operational execution
James E. Galvin, M.D., MPH
Professor of Neurology and Psychiatry, University of Miami
Director, Comprehensive Center for Brain Health
Dr. Galvin specializes in neurodegenerative diseases and cognitive disorders, with extensive experience in clinical research, translational medicine, and academic leadership.
Brian E. McGeeney, M.D., MPH, MBA
Lauren R. Natbony, M.D., FAHS
Founder, Integrative Headache Medicine of New York
Secretary General, World Headache Society
Faculty, Icahn School of Medicine at Mount Sinai
Dr. Natbony is a headache medicine specialist with clinical and academic expertise in cluster headache and related neurological disorders.
Martin K. Madsen, M.D., Ph.D.
Dr. Madsen is a neurobiology researcher specializing in serotonin 5-HT2A receptor mechanisms and psychedelic compounds, with expertise in PET and fMRI neuroimaging methodologies relevant to CNS drug development.
This page is provided for corporate and informational purposes only and does not constitute an offer or solicitation.